Ex vivo analysis of topotecan: Advancing the application of laboratory-based clinical therapeutics

British Journal of Cancer

Volumn 89, Issue 9, 2003, Pages 1789-1795

  Nagourney, R A ^a,b   Sommers, B L ^a   Harper, S M ^a   Radecki, S ^c   Evans, S S ^a  

^a Rational Therapeutics   (United States)

^b Malcolm C Todd Cancer Institute   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Cell death assay; Combination regimens; Ex vivo; Non small cell lung cancer; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORMETHINE; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MITOMYCIN C; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; TOPOTECAN;

ARTICLE; BIOPSY; BREAST CANCER; CELL ASSAY; CELL DEATH; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LC 50; LUNG SMALL CELL CANCER; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL SIGNIFICANCE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; LETHAL DOSE 50; LUNG NEOPLASMS; MALE; NEOPLASMS; PROSTATIC NEOPLASMS; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 0344440957     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601336     Document Type: Article

References (55)

1. Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J, Verweij J (1997) Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J Clin Oncol 15: 2090-2096
2. Ardizzoni A, Manegold C, Gaafar R, Buchholdz E, Debruyne C, Damen S, Curran D, King K, Giaccone G (1999) Combination chemotherapy with cisplatin and topotecan as second-line treatment of sensitive (S) and refractory (R) small cell lung cancer (SCLC): an EORTC LCCG phase II study (abstract). Proc Am Soc Clin Oncol 18: 471a
3. Beran M, Estey E, O'Brien SM, Giles FJ, Koller CA, Kornblau S, Keating M, Kantarjian HM (1998) Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia Lymphoma 31: 521-531
4. Bookman MA, Malmström H, Bolis G, Gordon A, Lissoni A, Krebs JB, Fields SZ (1998) Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16: 3345-3352
5. Bosanquet AG, Johnson SA, Richards SM (1999) Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DISC assay. Br J Haematol 106: 71-77
6. Brown III JV, Peters III WA, Rettenmaier MA, Karlan BY, Dillman RA, Smith MR, Drescher CW, Micha JP (2000) A phase I trial of a 3-day topotecan q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Gynecol Oncol 79: 495-498
7. Burke TG, Mi Z (1994) The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 37: 40-46
8. Cheadle C, Vawter MP, Freed WJ, Becker KG (2003) Analysis of microarray data using Z score transformation. J Mol Diagn 5: 73-81
9. Chou T-C, Talalay P (1987) Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents. In New Avenues in Developmental Cancer Chemotherapy Harrap KR, Connors TA (eds) pp 37-64. Orlando, FL: Academic Press Inc.
10. Clarke-Pearson DL, Van Le L, Iveson T, Whitney CW, Hanjani P, Kristensen G, Malfetano JH, Beckman RA, Ross GA, Lane SR, DeWitte MH, Fields SZ (2001) Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol 19: 3967-3975
11. Cortazar P, Johnson BE (1999) Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol 17: 1625-1631
12. Crawford J, O'Rourke M, Schiller JH, Spiridonidis CH, Yanovich S, Ozer H, Langleben A, Hutchins L, Koletsky A, Clamon G, Burman S, White R, Hohneker J, Spiridonidis CH (1996) Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol 14: 2774-2784
13. Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, Despax R, Favalli G, Kreinberg R, Van Belle S, Hudson I, Verweij J, ten Bokkel Huinink WW (1996) Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 14: 3056-3061
14. Depierre A, von Pawel J, Hans K, Moro D, Clark P, Gatzemeier U, Paillot N, Scheithauer W, Carmichael J, Santoro A, Ross G, Marangolo M (1997) Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study (abstract). Lung Cancer 18(Suppl. 1): 35
15. Eckardt J, Gralla R, Palmer MC, Gandara D, Laplante J, Sandler A, Fields SZ, Fitts D, Broom C (1996) Topotecan (T) as second-line therapy in patients (Pts) with small cell lung cancer (SCLC): a phase II study (abstract). Ann Oncol 7(Suppl. 5): 107
16. Feinstein AR (1998) Clinical Epidemiology: The Architecture of Clinical Research. Philadelphia: W.B. Sanders
17. Fiorica J, Holloway R, Ndubisi B, Orr J, Grendys E, Boothby R, DeCesare S, LaPolla J, Hoffman M, Patel J (2002) Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol 85: 89-94
18. Frasci G, Panza N, Comella P, Carteni G, Guida T, Nicolella GP, Natale M, Lombardi R, Apicella A, Pacilio C, Gravina A, Lapenta L, Comella G (1999) Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study. Ann Oncol 10: 355-358
19. Guarino MJ, Schneider CJ, Grubbs SS, Biggs DD, Himelstein AL, Hogaboom K, Tilak S (2002) A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer. Oncologist 7: 509-515
20. Hainsworth JD, Burris III HA, Morrissey LH, Greco FA (1999) Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer. Cancer 85: 1179-1185
21. Hays WL (1994) Statistics 5th edn. International Thomson Publishing.
22. Hochster H, Wadler S, Runowicz C, Liebes L, Cohen H, Wallach R, Sorich J, Taubes B, Speyer J (1999) Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. J Clin Oncol 17: 2553-2561
23. Homesley HD, Hall DJ, Martin DA, Lewandowski GS, Vaccarello L, Nahhas WA, Suggs CL, Penley RG (2001) A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol 83: 394-399
24. Hoskins P, Eisenhauer E, Beare S, Roy M, Drouin P, Stuart G, Bryson P, Grimshaw R, Capstick V, Zee B (1998) Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 16: 2233-2237
25. Hudes GR, Kosierowski R, Greenberg R, Ramsey HE, Fox SC, Ozols RF, McAleer CA, Giantonio BJ (1995) Phase II study of topotecan in metastatic hormone-refractory prostate cancer. Invest New Drugs 13: 235-240
26. Jacobs SA, Jett JR, Belani CP, Long GS, Day RD, Kim HD, Levitt ML, Woolley PV (1999) Topotecan and paclitaxel, an active couplet, in untreated extensive disease small cell lung cancer (abstract). Proc Am Soc Clin Oncol 18: 470a
27. Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher G, Caranfa MJ, McCabe FL, Faucette LF, Johnson RK, Hertzberg RP (1991) Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 34: 98-107
28. Kirk RE (1982) Experimental Design: Procedure for The Behavorial Sciences. Pacific Grove, CA: Brooks/Cole Publishing Company
29. Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroj P, Gonzalez de Leon C, Kim EE, Madden T, Wallin B, Hord M, Verschraegen C, Raber M, Kavanagh JJ (1996) Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14: 1552-1557
30. Lemkin PF, Thornwall CG, Walton KD, Hennighausen L (2000) Themicroarray explorer to for data mining of cDNA microarrays: application for the mammary gland. Nucleic Acids Res 28: 4452-4459
31. Levine G (1991) A Guide to SPSS for Analysis of Variance. Hove: Lawrence Erlbaum Associates
32. Levine EG, Cirrincione CT, Szatrowski TP, Canellos G, Norton L, Henderson IC (1999) Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study. Am J Clin Oncol 22: 218-222
33. Lynch Jr TJ, Kalish L, Strauss G, Elias A, Skarin A, Shulman LN, Posner M, Frei III E (1994) Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 12: 347-352
34. McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ (2000) Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 18: 1062-1067
35. Nagourney R, Brewer C, Radecki S, Kidder W, Sommers B, Evans S, Minor D, DiSaia PJ (2003) A phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol 88: 35-39
36. Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS (2000) Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 18: 2245-2249
37. O'Neill P, Clark PI, Smith D, Marshall E, Hannigan K, Ross G (2001) A phase I trial of a 5-day schedule of intravenous topotecan and etoposide in previously untreated patients with small-cell lung cancer. Oncology 61(Suppl. 1): 25-29
38. Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Kane J, Robinson RA, Lippman SM, Kurie JM, Huber MH, Raber MN, Hong WK (1996) Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 14: 503-513
39. Pujol JL, von Pawel J, Tumolo S, Martoni A, Hearn S, Fields SZ, Ross G (2001) Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer. Oncology 61(Suppl. 1): 47-54
40. Raymond E, Burris HA, Rowinsky EK, Eckardt JR, Rodriguez G, Smith L, Weiss G, Von Hoff DD (1997) Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma. Ann Oncol 8: 1003-1008
41. Reed JC (1999) Dysregulation of apoptosis in cancer. J Clin Oncol 17: 2941-2953
42. Rothenberg ML (1997) Topoisomerase I inhibitors: review and update. Ann Oncol 8: 837-855
43. Sehouli J, Lichtenegger W, Hindenburg HJ, Klare P, Keil E, Heinrich G, Elling D, Hieronimus-Reichel A, Oskay G, Blohmer J, Camara O, Ledwon P, Stengel D (2001) A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with platin and paclitaxel (abstract). Proc Am Soc Clin Oncol 20: 216a
44. Shi LM, Myers TG, Fan Y, O'Connor PM, Paull KD, Friend SH, Weinstein JN (1998) Mining the National Cancer Institute anticancer drug discovery database: cluster analysis of ellipticine analogs with p53-invese and central nervous system-selective patterns of activity. Mol Pharmacol 53: 241-251
45. Stupp R, Bodmer A, Duvoisin B, Bauer J, Perey L, Bakr M, Ketterer N, Leyvraz S (2001) Is cisplatin required for the treatment of non-small-cell lung cancer. Experience and preliminary results of a phase I/II trial with topotecan and vinorelbine. Oncology 61(Suppl. 1): 35-41
46. Su Y-Z, Sommers B, Horlick D, Harris C, Evans S, Nagourney R (2001) Synergy between topotecan and other cytotoxic drugs in human tumors (abstract). Proc Am Assoc Cancer Res 42: 253-254
47. Taguchi T, Tominaga T, Ogawa M, Ishida T, Morimoto K, Ogawa N (1994) A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. CPT-11 Study Group on Breast Cancer). Gan To Kagaku Ryoho 21: 1017-1024
48. ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmström H, Coleman R, Fields SC, Heron JF (1997) Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15: 2183-2193
49. The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91: 66-72
50. Verweij J, Lund B, Beijnen J, Planting A, de Boer-Dennert M, Koier I, Rosing H, Hansen H (1993) Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 4: 673-678
51. von Pawel J, Gatzemeier U, Pujol JL, Moreau L, Bildat S, Ranson M, Richardson G, Steppert C, Riviere A, Camlett I, Lane S, Ross G (2001) Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 19: 1743-1749
52. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR, Gralla R (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17: 658-667
53. Wall JG, Burris III HA, Von Hoff DD, Rodriguez G, Kneuper-Hall R, Shaffer D, O'Rourke T, Brown T, Weiss G, Clark G, McVea S, Brown J, Johnson R, Friedman C, Smith B, Mann WS, Kuhn J (1992) A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs 3: 337-345
54. Weitz JJ, Marschke Jr RF, Sloan JA, Grill JP, Jett JR, Knost JA, Hatfield AK, Zenk DW, Bate WW, Schaefer PL (2000) A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. Lung Cancer 28: 157-162
55. Wiesenfeld M, Marks R, Grill J, Sloan J, Tazelaar H, Carroll T, Kugler J, Krook J (1997) A randomized phase II study of topotecan (TOPA) and cisplatin (CDDP) with filgrastim (G-CSF) versus topotecan and paclitaxel (Taxol®) with filgrastim in patients with advanced non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol 16: 488a